Substance / Medication

Momelotinib

Overview

Active Ingredient
momelotinib
RxNorm CUI
2665204

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia.
Yoon Sung-Soo, Chen Chih Cheng, Lee Sung-Eun et al. · Int J Hematol · 2025
PMID: 40691344RCTFull text (PMC)
Evaluation of the Effect of Momelotinib on Cardiac Repolarization: A Thorough QT Study.
Vlasakakis Georgios, Alvarez Yolanda, Hart Timothy et al. · Clin Pharmacol Drug Dev · 2025
PMID: 39844679RCTFull text (PMC)
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
Gupta Vikas, Oh Stephen, Devos Timothy et al. · Leuk Lymphoma · 2024
PMID: 38501751RCT
Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study.
Martorelli Maria Carmen, Pugliese Novella, Di Perna Maria et al. · Eur J Haematol · 2026
PMID: 40955124ObservationalFull text (PMC)
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis.
Masarova Lucia, Verstovsek Srdan, Palandri Francesca et al. · Future Oncol · 2025
PMID: 40476686ObservationalFull text (PMC)
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis.
Masarova Lucia, Verstovsek Srdan, Palandri Francesca et al. · Future Oncol · 2025
PMID: 40476514ObservationalFull text (PMC)
MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.
Jilg Stefanie, Schwaab Juliana, Sockel Katja et al. · Ann Hematol · 2024
PMID: 39073589Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Momelotinib (substance)
SNOMED CT
1366447007
UMLS CUI
C2744845
RxNorm CUI
2665204

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.